These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38748320)

  • 1. Myasthenia Gravis Disease Burden and Its Impact on Satisfaction with Life: A Qualitative Survey of Patients' Perspectives in Japan.
    Kawaguchi N; Tsuda K; Tanaka N; Kerstens R; Harada D
    Neurol Ther; 2024 Aug; 13(4):1099-1113. PubMed ID: 38748320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient's Perspective: A Qualitative Study.
    Jackson K; Parthan A; Lauher-Charest M; Broderick L; Law N; Barnett C
    Neurol Ther; 2023 Feb; 12(1):107-128. PubMed ID: 36322146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies in Japanese patients with ocular myasthenia gravis.
    Nagaishi A; Narita T; Woodhall M; Jacobson L; Waters P; Irani SR; Vincent A; Matsuo H
    Muscle Nerve; 2021 Feb; 63(2):262-267. PubMed ID: 33094484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case Report of MuSK Antibody-Positive Myasthenia Gravis.
    Gayathri D; Nandasiri S; Pathirana G
    Cureus; 2024 Jun; 16(6):e61820. PubMed ID: 38975540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
    Lazaridis K; Tzartos SJ
    Front Immunol; 2020; 11():212. PubMed ID: 32117321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
    Vakrakou AG; Karachaliou E; Chroni E; Zouvelou V; Tzanetakos D; Salakou S; Papadopoulou M; Tzartos S; Voumvourakis K; Kilidireas C; Giannopoulos S; Tsivgoulis G; Tzartos J
    Front Immunol; 2023; 14():1212757. PubMed ID: 37564637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
    Leite MI; Jacob S; Viegas S; Cossins J; Clover L; Morgan BP; Beeson D; Willcox N; Vincent A
    Brain; 2008 Jul; 131(Pt 7):1940-52. PubMed ID: 18515870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.
    Lazaridis K; Tzartos SJ
    Front Neurol; 2020; 11():596981. PubMed ID: 33329350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis.
    Damato V; Spagni G; Monte G; Woodhall M; Jacobson L; Falso S; Smith T; Iorio R; Waters P; Irani SR; Vincent A; Evoli A
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):995-1000. PubMed ID: 35835469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in patients with MuSK positive myasthenia gravis.
    Stankovic M; Peric S; Stojiljkovic Tamas O; Stankovic T; Nikolic A; Lavrnic D; Basta I
    Acta Neurol Belg; 2018 Sep; 118(3):423-427. PubMed ID: 29594965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
    Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
    J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibody detection by a live cell-based assay in conventionally antibody-tested triple seronegative Myasthenia gravis.
    Hoffmann S; Waters P; Jacobson L; Schuelke M; Stenzel W; Ruck T; Lehnerer S; Stascheit F; Preuße C; Meisel A
    Neuromuscul Disord; 2023 Feb; 33(2):139-144. PubMed ID: 36746691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathophysiologic relevance of autoantibodies in neonatal myasthenia gravis.
    Iijima S
    Pediatr Neonatol; 2021 Nov; 62(6):581-590. PubMed ID: 34272198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
    Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
    Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature.
    de Meel RHP; Raadsheer WF; van Zwet EW; Tannemaat MR; Verschuuren JJGM
    J Neuromuscul Dis; 2019; 6(3):369-376. PubMed ID: 31424417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features.
    Park KH; Waters P; Woodhall M; Lang B; Smith T; Sung JJ; Kim KK; Lim YM; Kim JE; Kim BJ; Park JS; Lim JG; Kim DS; Kwon O; Sohn EH; Bae JS; Yoon BN; Kim NH; Ahn SW; Oh J; Park HJ; Shin KJ; Hong YH
    PLoS One; 2018; 13(3):e0193723. PubMed ID: 29518096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-seronegative myasthenia gravis: clinical and epidemiological characteristics.
    Rodrigues PRDVP; Kay CSK; Ducci RD; Utiumi MAT; Fustes OJH; Werneck LC; Lorenzoni PJ; Scola RH
    Arq Neuropsiquiatr; 2024 Jan; 82(1):1-7. PubMed ID: 38316426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies.
    Beland B; Hahn C; Jamani K; Chhibber S; White C; Atkins H; Storek J
    Muscle Nerve; 2023 Feb; 67(2):154-157. PubMed ID: 36527328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.